Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Teva Pharmaceutical Industries Trading Up 0.1 %
NYSE TEVA opened at $16.51 on Wednesday. The stock’s 50-day simple moving average is $15.79 and its two-hundred day simple moving average is $13.57. Teva Pharmaceutical Industries Limited has a twelve month low of $7.42 and a twelve month high of $17.69. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $18.69 billion, a price-to-earnings ratio of -40.26, a PEG ratio of 1.62 and a beta of 0.91.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The firm had revenue of $3.82 billion for the quarter, compared to analysts’ expectations of $3.70 billion. Research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.3 EPS for the current fiscal year.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Analyst Upgrades and Downgrades
A number of research firms have recently commented on TEVA. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a research note on Friday, March 8th. Barclays lifted their price objective on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. Finally, Bank of America lifted their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.88.
View Our Latest Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Stories
- Five stocks we like better than Teva Pharmaceutical Industries
- The 3 Best Fintech Stocks to Buy Now
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- EV Stocks and How to Profit from Them
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- Airline Stocks – Top Airline Stocks to Buy Now
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.